Literature DB >> 9114003

The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton.

X Tong1, P M Howley.   

Abstract

The E6 oncoprotein of bovine papillomavirus type 1 (BPV-1) has been shown to transform cells through a p53-independent pathway, but its transforming mechanism is unknown. Here we demonstrate in vitro and in vivo interactions between BPV-1 E6 and the focal adhesion protein paxillin. The ability of BPV-1 E6 to complex with paxillin correlated with its ability to transform; E6 mutant proteins impaired in their transformation function also were impaired in their abilities to bind paxillin. E6 binding to paxillin also may contribute to the carcinogenic potential of the human papillomavirus (HPV); we were able to show in vitro binding of paxillin to the E6 proteins of the cancer-associated type HPV 16 but not of the nononcogenic types 6 and 11. The association of E6 with paxillin was affected by depolymerization of the actin fiber network, and overexpression of BPV-1 E6 led to disruption of actin fiber formation. Disruption of the actin cytoskeleton is a characteristic of many transformed cells, and, in BPV-1 transformed cells, may be mediated by BPV-1 E6 through its interaction with paxillin.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9114003      PMCID: PMC20736          DOI: 10.1073/pnas.94.9.4412

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Transformation by Rho exchange factor oncogenes is mediated by activation of an integrin-dependent pathway.

Authors:  M A Schwartz; D Toksoz; R Khosravi-Far
Journal:  EMBO J       Date:  1996-12-02       Impact factor: 11.598

2.  E5 open reading frame of bovine papillomavirus type 1 encodes a transforming gene.

Authors:  J T Schiller; W C Vass; K H Vousden; D R Lowy
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

3.  Cytoskeletal organization affects cellular responses to cytochalasins: comparison of a normal line and its transformant.

Authors:  J G Brett; G C Godman
Journal:  Tissue Cell       Date:  1986       Impact factor: 2.466

4.  Bovine papillomavirus contains multiple transforming genes.

Authors:  Y C Yang; H Okayama; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

5.  Genetic analysis of the 3' early region transformation and replication functions of bovine papillomavirus type 1.

Authors:  D E Groff; W D Lancaster
Journal:  Virology       Date:  1986-04-15       Impact factor: 3.616

6.  Identification of a second transforming region in bovine papillomavirus DNA.

Authors:  J T Schiller; W C Vass; D R Lowy
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

7.  Localization and analysis of bovine papillomavirus type 1 transforming functions.

Authors:  N Sarver; M S Rabson; Y C Yang; J C Byrne; P M Howley
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

8.  Telomerase activation by the E6 gene product of human papillomavirus type 16.

Authors:  A J Klingelhutz; S A Foster; J K McDougall
Journal:  Nature       Date:  1996-03-07       Impact factor: 49.962

9.  Identification of the protein encoded by the E6 transforming gene of bovine papillomavirus.

Authors:  E J Androphy; J T Schiller; D R Lowy
Journal:  Science       Date:  1985-10-25       Impact factor: 47.728

10.  Direct association of pp125FAK with paxillin, the focal adhesion-targeting mechanism of pp125FAK.

Authors:  K Tachibana; T Sato; N D'Avirro; C Morimoto
Journal:  J Exp Med       Date:  1995-10-01       Impact factor: 14.307

View more
  77 in total

1.  Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase.

Authors:  S Nakagawa; J M Huibregtse
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

Review 2.  Molecular interactions of 'high risk' human papillomaviruses E6 and E7 oncoproteins: implications for tumour progression.

Authors:  Oishee Chakrabarti; Sudhir Krishna
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

Review 3.  Mechanisms of human papillomavirus-induced oncogenesis.

Authors:  Karl Münger; Amy Baldwin; Kirsten M Edwards; Hiroyuki Hayakawa; Christine L Nguyen; Michael Owens; Miranda Grace; Kyungwon Huh
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

4.  Cutaneous β-human papillomavirus E6 proteins bind Mastermind-like coactivators and repress Notch signaling.

Authors:  Min Jie Alvin Tan; Elizabeth A White; Mathew E Sowa; J Wade Harper; Jon C Aster; Peter M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

5.  A transformation-associated complex involving tyrosine kinase signal adapter proteins and caldesmon links v-erbB signaling to actin stress fiber disassembly.

Authors:  M J McManus; W L Lingle; J L Salisbury; N J Maihle
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

6.  Role of the PDZ domain-binding motif of the oncoprotein E6 in the pathogenesis of human papillomavirus type 31.

Authors:  Choongho Lee; Laimonis A Laimins
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

7.  The interaction between human papillomavirus type 16 and FADD is mediated by a novel E6 binding domain.

Authors:  Sandy S Tungteakkhun; Maria Filippova; Jonathan W Neidigh; Nadja Fodor; Penelope J Duerksen-Hughes
Journal:  J Virol       Date:  2008-07-16       Impact factor: 5.103

Review 8.  Papillomavirus E6 oncoproteins.

Authors:  Scott B Vande Pol; Aloysius J Klingelhutz
Journal:  Virology       Date:  2013-05-24       Impact factor: 3.616

9.  Transformation by bovine papillomavirus type 1 E6 requires paxillin.

Authors:  Ramon Wade; Nicole Brimer; Scott Vande Pol
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

10.  Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein.

Authors:  K Butz; C Denk; A Ullmann; M Scheffner; F Hoppe-Seyler
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.